Health
New gene therapy could treat dominant optic atrophy – Drug Target Review
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Posted: 27 November 2020 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Scientists have developed a new gene therapy approach that they say offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study was led by researchers at Trinity College Dublin, Ireland.
A fluorescent microscope…
-
Business16 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business12 hours agoDicker Data rides the AI trend to double digit growth
-
Business20 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Noosa News20 hours agoOld Translink app canned, and new version ‘worse than paper map from 2015’